Virax Biolabs Group Limited (Nasdaq: VRAX) has filed a Form 6-K announcing an Extraordinary General Meeting of Shareholders to be held on August 14, 2026. The primary purpose of the meeting is to vote on a proposal to significantly increase the company\'s authorized share capital. Specifically, the board seeks to increase the authorized capital from US$50,000 (divided into 2,000,000 ordinary shares) to US$12,500,000 (divided into 500,000,000 ordinary shares). The company stated that this 250-fold increase in authorized shares is intended to meet basic financing needs for operations and to provide flexibility for potential business development transactions. Crucially, the additional capital is designated to support the continued clinical and regulatory development of ViraxImmune™, the company\'s proprietary T-cell testing platform. Shareholders will also vote on a related Charter Amendment to reflect this capital structure change and an Adjournment Proposal if further proxy solicitation is required. The Board of Directors unanimously recommends a vote "FOR" all proposals to ensure sufficient funding for the company\'s commercial and clinical objectives.